Cingulate Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder, relocated to an expanded research and development headquarters at 1901 Olathe Blvd. in Kansas City, Kansas.
The firm previously had offices at the University of Kansas Bioscience and Technology Business Center in Kansas City, Kansas. The move is intended to accommodate Cingulate's growth in transition into a clinical stage development company.
Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 and CTX-1302, for the treatment of Attention Deficit/Hyperactivity Disorder in children, adolescents and adults. The Company recently announced that it has initiated an in vivo proof of concept trial of its compound CTX-1301 and intends to submit Investigational New Drug (applications to the U.S. Food & Drug Administration for both CTX-1301 and CTX-1302 by the end of 2017.
"Cingulate is proud to have partnered with the University of Kansas Bioscience and Technology Business Center for the last three years and will continue to support their efforts in Lawrence and Kansas City for years to come. Having initiated human trials earlier this quarter and with the need to accommodate growth in pursuit of aggressive clinical development plans we are excited to move our Kansas City operations to the Heartland House, the former headquarters of Aratana Therapeutics," said Shane J. Schaffer, PharmD, Chairman & CEO of Cingulate Therapeutics.
GR Underwood, President of the Bioscience & Technology Business Center, said, "Our mission has been to deliver jobs to the local economy by helping cutting edge businesses establish themselves and flourish. We are proud of Cingulate's maturation into the clinical stage and are excited to see the future developments that come out of their expanded headquarters."